Table 3.
Agreement analysis1 comparing information from self-administered questionnaires with medical record information in 939 women with breast cancer.
| Proportion correct (%) |
Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Kappa | |
|---|---|---|---|---|---|---|
| Hormone therapy | 92.6 | 93.2 | 95.0 | 95.7 | 92.2 | 0.88 |
| Chemotherapy | 93.6 | 97.2 | 96.6 | 92.4 | 96.6 | 0.88 |
| Radiation treatment2 | 98.3 | 99.8 | 96.4 | 99.00 | 99.5 | 0.97 |
| Surgery | 99.0 | 99.7 | — | 99.7 | — | — |
| Breast cancer recurrence | 94.8 | 75.5 | 97.3 | 60.7 | 98.6 | 0.65 |
| Menopausal status3 | 95.6 | — | — | — | — | 0.89 |
| Menopausal status4 | 83.0 | 0.71 | ||||
| Hormonal medication | ||||||
| Tamoxifen | 89.9 | 91.1 | 80.9 | 97.3 | 54.8 | 0.60 |
| Megestrol | 97.9 | 31.2 | 100.0 | 100.0 | 97.9 | 0.47 |
| Anastrozole | 89.8 | 17.6 | 99.1 | 75.0 | 89.2 | 0.25 |
| MA12 | 95.7 | 54.5 | 97.5 | 48.0 | 98.9 | 0.49 |
| Chemotherapy medication | ||||||
| Cyclophosphamide | 55.4 | 56.6 | 40.5 | 91.9 | 7.3 | −0.01 |
| Flurouracil | 60.2 | 55.2 | 79.8 | 91.5 | 31.1 | 0.22 |
| Methotrexate | 77.0 | 49.3 | 95.1 | 86.9 | 74.2 | 0.48 |
| Epirubicin | 82.4 | 54.7 | 97.4 | 92.0 | 78.9 | 0.57 |
| Doxorubicin | 83.5 | 48.3 | 96.9 | 85.7 | 83.1 | 0.52 |
| Docetaxel | 89.4 | 6.7 | 99.8 | 80.0 | 89.5 | 0.11 |
| Surgery | ||||||
| Mastectomy | 99.8 | 96.2 | 99.5 | 96.5 | 98.3 | 0.95 |
| Lumpectomy | 93.4 | 99.1 | 97.5 | 91.9 | 97.5 | 0.84 |
1Agreement analysis was conducted excluding unknown and missing responses.
2Agreement analysis for radiation therapy was conducted excluding women with breast cancer recurrence (according to medical records).
3Calculated excluding unknown and missing information (i.e. treating menopausal status as a 2-level variable of premenopausal and postmenopausal).
4Calculated including unknown and missing information (i.e. treating menopausal status as a 3-level variable of premenopausal, postmenopausal, and unknown/missing. Unknown/missing information that match between medical records and treatment questionnaire data are treated as in agreement).